Menu Search
Equities

Shanghai Junshi Biosciences Co Ltd

SHJBF:PKC

Shanghai Junshi Biosciences Co Ltd

Actions
  • Price (USD)1.24
  • Today's Change0.00 / 0.00%
  • Shares traded2.04k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024 18:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.

  • Revenue in HKD (TTM)1.77bn
  • Net income in HKD-2.11bn
  • Incorporated2012
  • Employees2.53k
  • Location
    Shanghai Junshi Biosciences Co Ltd16F, Building 7, No. 6, Lane 100Pingjiaqiao Road, Pudong New AreaSHANGHAI 201203ChinaCHN
  • Phone+86 2 161058800
  • Fax+86 2 161757377
  • Websitehttps://www.junshipharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.